ID   Hepa 1-6
AC   CVCL_0327
SY   HEPA 1-6; Hepa-1-6; Hepa1-6
DR   BTO; BTO:0002895
DR   CLO; CLO_0003711
DR   CLO; CLO_0050769
DR   MCCL; MCC:0000223
DR   CLDB; cl1658
DR   CLDB; cl1659
DR   CLDB; cl5199
DR   AddexBio; C0015005/4999
DR   ATCC; CRL-1830
DR   BCRC; 60051
DR   BioSample; SAMN11397636
DR   CCRID; 1101MOU-PUMC000106
DR   CCRID; 3101MOUSCSP512
DR   CCRID; 3101MOUTCM39
DR   CCRID; 4201MOU-CCTCC00313
DR   CCRID; 6101MOU-CERC000105
DR   CCTCC; GDC0313
DR   CLS; 400474
DR   DSMZ; ACC-175
DR   DSMZCellDive; ACC-175
DR   ECACC; 92110305
DR   GEO; GSM1374085
DR   GEO; GSM1374086
DR   GEO; GSM1374087
DR   GEO; GSM1374088
DR   GEO; GSM1374089
DR   GEO; GSM1374090
DR   IZSLER; BS TCL 157
DR   Lonza; 830
DR   NCBI_Iran; C517
DR   PRIDE; PXD001792
DR   RCB; RCB1638
DR   Ubigene; YC-A005
DR   Wikidata; Q54882820
RX   PubMed=11004682;
RX   PubMed=12606785;
RX   PubMed=25193168;
RX   PubMed=26280412;
RX   PubMed=28152020;
RX   PubMed=31220119;
CC   Doubling time: 26.99 +- 1.93 hours (PubMed=28152020); ~30 hours (DSMZ=ACC-175).
CC   Omics: Deep phosphoproteome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Liver; UBERON=UBERON_0002107.
CC   Breed/subspecies: C57L.
ST   Source(s): PubMed=31220119; Ubigene
ST   Mouse STR 1-1: 14,15,16
ST   Mouse STR 1-2: 13
ST   Mouse STR 11-2: 16
ST   Mouse STR 12-1: 17
ST   Mouse STR 13-1: 17.1
ST   Mouse STR 15-3: 17,18,19
ST   Mouse STR 17-2: 14
ST   Mouse STR 18-3: 16,17
ST   Mouse STR 19-2: 10,11
ST   Mouse STR 2-1: 14
ST   Mouse STR 3-2: 10
ST   Mouse STR 4-2: 18.3,19.3
ST   Mouse STR 5-5: 17
ST   Mouse STR 6-4: 18,19
ST   Mouse STR 6-7: 15
ST   Mouse STR 7-1: 25.2
ST   Mouse STR 8-1: 15
ST   Mouse STR X-1: 25
DI   NCIt; C38756; Hepatocellular carcinoma of the mouse
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_S550 ! Hepa-1
SX   Female
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 25
//
RX   PubMed=11004682; DOI=10.1002/1097-0215(20001015)88:2<287::AID-IJC22>3.0.CO;2-U;
RA   Briz O., Serrano M.A., Macias R.I.R., Marin J.J.G.;
RT   "Overcoming cisplatin resistance in vitro by a free and
RT   liposome-encapsulated bile acid derivative: BAMET-R2.";
RL   Int. J. Cancer 88:287-292(2000).
//
RX   PubMed=12606785; DOI=10.1124/mol.63.3.742;
RA   Briz O., Macias R.I.R., Vallejo M., Silva A., Serrano M.A.,
RA   Marin J.J.G.;
RT   "Usefulness of liposomes loaded with cytostatic bile acid derivatives
RT   to circumvent chemotherapy resistance of enterohepatic tumors.";
RL   Mol. Pharmacol. 63:742-750(2003).
//
RX   PubMed=25193168; DOI=10.1074/mcp.M113.037291;
RA   Hornburg D., Drepper C., Butter F., Meissner F., Sendtner M., Mann M.;
RT   "Deep proteomic evaluation of primary and cell line motoneuron disease
RT   models delineates major differences in neuronal characteristics.";
RL   Mol. Cell. Proteomics 13:3410-3420(2014).
//
RX   PubMed=26280412; DOI=10.1038/nbt.3327;
RA   Humphrey S.J., Azimifar S.B., Mann M.;
RT   "High-throughput phosphoproteomics reveals in vivo insulin signaling
RT   dynamics.";
RL   Nat. Biotechnol. 33:990-995(2015).
//
RX   PubMed=28152020; DOI=10.1371/journal.pone.0171215;
RA   Lacoste B., Raymond V.-A., Cassim S., Lapierre P., Bilodeau M.;
RT   "Highly tumorigenic hepatocellular carcinoma cell line with cancer
RT   stem cell-like properties.";
RL   PLoS ONE 12:E0171215-E0171215(2017).
//
RX   PubMed=31220119; DOI=10.1371/journal.pone.0218412;
RA   Almeida J.L., Dakic A., Kindig K., Kone M., Letham D.L.D., Langdon S.,
RA   Peat R., Holding-Pillai J., Hall E.M., Ladd M., Shaffer M.D., Berg H.,
RA   Li J.-L., Wigger G., Lund S., Steffen C.R., Fransway B.B., Geraghty B.,
RA   Natoli M., Bauer B.A., Gollin S.M., Lewis D.W., Reid Y.A.;
RT   "Interlaboratory study to validate a STR profiling method for
RT   intraspecies identification of mouse cell lines.";
RL   PLoS ONE 14:E0218412-E0218412(2019).
//